A Phase 1, Multi-cohort, Open-label Study to Evaluate the Relative Bioavailability of Capsule and Tablet Formulations of TYRA-300-B01, and to Evaluate the Safety, Tolerability, and Food Effect of TYRA-300-B01 Tablets in Healthy Adult Participants
Latest Information Update: 31 Mar 2025
At a glance
- Drugs TYRA-300 (Primary)
- Indications Achondroplasia; Bladder cancer; Hypochondroplasia; Solid tumours
- Focus Pharmacokinetics
- Sponsors Tyra Biosciences
Most Recent Events
- 26 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2025 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 27 Jan 2025 Planned primary completion date changed from 1 May 2024 to 1 May 2025.